JP2024527324A5 - - Google Patents
Info
- Publication number
- JP2024527324A5 JP2024527324A5 JP2023580722A JP2023580722A JP2024527324A5 JP 2024527324 A5 JP2024527324 A5 JP 2024527324A5 JP 2023580722 A JP2023580722 A JP 2023580722A JP 2023580722 A JP2023580722 A JP 2023580722A JP 2024527324 A5 JP2024527324 A5 JP 2024527324A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- fab
- dimer
- conjugate
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163217743P | 2021-07-01 | 2021-07-01 | |
| US63/217,743 | 2021-07-01 | ||
| US202263298193P | 2022-01-10 | 2022-01-10 | |
| US63/298,193 | 2022-01-10 | ||
| US202263333449P | 2022-04-21 | 2022-04-21 | |
| US63/333,449 | 2022-04-21 | ||
| PCT/US2022/073377 WO2023279099A1 (en) | 2021-07-01 | 2022-07-01 | Oligonucleotide conjugates targeted to the transferrin receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527324A JP2024527324A (ja) | 2024-07-24 |
| JP2024527324A5 true JP2024527324A5 (https=) | 2025-07-09 |
Family
ID=83004986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580722A Pending JP2024527324A (ja) | 2021-07-01 | 2022-07-01 | トランスフェリン受容体を標的とするオリゴヌクレオチド抱合体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240299575A1 (https=) |
| EP (1) | EP4362985A1 (https=) |
| JP (1) | JP2024527324A (https=) |
| KR (1) | KR20240029759A (https=) |
| CA (1) | CA3225542A1 (https=) |
| CL (1) | CL2023003958A1 (https=) |
| CO (1) | CO2023017250A2 (https=) |
| CR (1) | CR20240042A (https=) |
| IL (1) | IL309346A (https=) |
| MX (1) | MX2023015520A (https=) |
| PE (1) | PE20250121A1 (https=) |
| TW (1) | TW202315638A (https=) |
| WO (1) | WO2023279099A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3263388A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | VIRAL PARTICLES RETRIBUTED TO TRANSFERRIN RECEPTOR 1 |
| KR20250058123A (ko) | 2022-07-29 | 2025-04-29 | 리제너론 파마슈티칼스 인코포레이티드 | 항-TfR:페이로드 융합 및 이의 사용 방법 |
| CN120659627A (zh) | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法 |
| IL326018A (en) | 2023-07-28 | 2026-03-01 | Regeneron Pharma | Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease |
| US20250049896A1 (en) | 2023-07-28 | 2025-02-13 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency |
| US20250064958A1 (en) * | 2023-08-22 | 2025-02-27 | Eli Lilly And Company | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENTS |
| WO2025151408A1 (en) * | 2024-01-08 | 2025-07-17 | Denali Therapeutics Inc. | Compositions and methods for modulating tau expression |
| WO2025151406A1 (en) * | 2024-01-08 | 2025-07-17 | Denali Therapeutics Inc. | Chemically modified oligonucleotides and conjugates and methods thereof |
| WO2025166111A1 (en) * | 2024-02-02 | 2025-08-07 | Eli Lilly And Company | Conjugates comprising transferrin receptor binding protein |
| WO2026072446A1 (en) * | 2024-09-25 | 2026-04-02 | Eli Lilly And Company | Conjugates comprising bis-mspt linker |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6773885B1 (en) | 2000-09-29 | 2004-08-10 | Integrated Dna Technologies, Inc. | Compositions and methods for visual ribonuclease detection assays |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| CN110506055A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| TW201934573A (zh) * | 2018-01-10 | 2019-09-01 | 美商戴納立製藥公司 | 轉鐵蛋白受體結合性多肽及其用途 |
-
2022
- 2022-07-01 WO PCT/US2022/073377 patent/WO2023279099A1/en not_active Ceased
- 2022-07-01 US US18/568,076 patent/US20240299575A1/en active Pending
- 2022-07-01 JP JP2023580722A patent/JP2024527324A/ja active Pending
- 2022-07-01 MX MX2023015520A patent/MX2023015520A/es unknown
- 2022-07-01 KR KR1020247001187A patent/KR20240029759A/ko active Pending
- 2022-07-01 TW TW111124841A patent/TW202315638A/zh unknown
- 2022-07-01 EP EP22757783.0A patent/EP4362985A1/en active Pending
- 2022-07-01 PE PE2023003484A patent/PE20250121A1/es unknown
- 2022-07-01 IL IL309346A patent/IL309346A/en unknown
- 2022-07-01 CA CA3225542A patent/CA3225542A1/en active Pending
-
2023
- 2023-12-13 CO CONC2023/0017250A patent/CO2023017250A2/es unknown
- 2023-12-28 CL CL2023003958A patent/CL2023003958A1/es unknown
-
2024
- 2024-01-26 CR CR20240042A patent/CR20240042A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024527324A5 (https=) | ||
| ES3008567T3 (en) | Recombinant antibody molecule and its use for target cell restricted t cell activation | |
| JP4773097B2 (ja) | ヒトインスリン受容体を介する医薬品の送達 | |
| JP2023529981A (ja) | 免疫活性化Ｆｃドメイン結合分子 | |
| US8142781B2 (en) | Fusion proteins for blood-brain barrier delivery | |
| EP3749372B1 (en) | Edb targeting il-12 compositions | |
| KR20240029759A (ko) | 트랜스페린 수용체에 표적화된 올리고뉴클레오티드 접합체 | |
| CN107484416A (zh) | 能够结合cd19和cd3的双特异性单价双抗体及其用途 | |
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| EP4547716A2 (en) | Transferrin receptor binding molecule conjugates for delivery of oligonucleotides to cells | |
| CN120018857A (zh) | Gprc5d tcb与imid的组合疗法 | |
| JP2023504531A (ja) | 腫瘍治療のための二重特異性融合タンパク質と抗Ｈｅｒ２抗体の組合せ | |
| WO2025117894A2 (en) | Dimeric immunoconjugates for use in treating cancers and methods of use | |
| TW202502378A (zh) | 抗ＥＧＦＲｖＩＩＩ／抗ＣＤ３抗體與靶向腫瘤之４－１ＢＢ促效劑的組合療法 | |
| KR20230154921A (ko) | 골격근 질환을 치료하기 위한 조성물 및 방법 | |
| HK40108042A (zh) | 靶向转铁蛋白受体的寡核苷酸缀合物 | |
| WO2024050648A1 (en) | Treatment of chemo-resistant tumors using multabodies | |
| WO2025151406A1 (en) | Chemically modified oligonucleotides and conjugates and methods thereof | |
| WO2025179086A9 (en) | Anti-ret antibodies as cancer therapeutics and diagnostic tools | |
| US20200223927A1 (en) | Methods and compositions for treating multiple sclerosis | |
| NZ716697A (en) | Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof | |
| NZ716697B2 (en) | Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof |